2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 488

Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Abstract Number: 624

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Oral Disease Management: Caries Prevention
Abstract Number: 622

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes
Abstract Number: 625

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Abstract Number: 640

Sjögren’s Syndrome in Male Patients Presents with Higher Autoantibody Levels and More Extraglandular Manifestations
Abstract Number: 840

Skin Telangiectasia Identify a Subset of Systemic Sclerosis Patients with Severe Vascular Phenotype
Abstract Number: 812

SLAMF3 Mediated Co-Stimulation Promotes Activation of the IL-2/IL-2R/STAT5 Pathway and Regulatory T Cells Differentiation in Human Naïve CD4+ T Cells – Implications for SLE
Abstract Number: 777

SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
Abstract Number: 2170

Sleep Efficiency and Cardiovascular Risk Burden in Rheumatoid Arthritis
Abstract Number: 1732

Slow Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Abstract Number: 2185

Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Abstract Number: 1826

Small LDL-P Increases with Increased Disease Activity in SLE
Abstract Number: 338

Smoking and Alcohol Use Are Associated with Structural and Inflammatory Hand Osteoarthritis Features in a Population Based Study
Abstract Number: 333

Smoking and Knee and Hip Osteoarthritis Evolution. Results from the Knee and Hip Osteoarthritis Long-Terme Assessment Cohort
Abstract Number: 909

Smoking Behavior Changes after Rheumatoid Arthritis Diagnosis and Risk of Mortality during 36 Years of Prospective Follow-up

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].